Nasal Spray Neuropeptide Y Reduced Depression Scores by 10 Points Within 24 Hours in First Human Trial
A single intranasal dose of 6.8 mg neuropeptide Y reduced depression scores significantly at 24 hours (d=0.67) vs placebo in 30 MDD patients already on antidepressants.
Quick Facts
What This Study Found
Single-dose intranasal NPY (6.8 mg) reduced MADRS by 10.3 points at 24h vs 5.6 for placebo (P=0.04, d=0.67) in MDD patients; effect not significant at 48h.
Key Numbers
6.8 mg single dose; MADRS -10.3 vs -5.6 at 24h (p=0.04, d=0.67); -7.1 vs -3.5 at 5h (p=0.05, d=0.61); 48h NS
How They Did This
Double-blind RCT: 30 MDD patients on stable antidepressants; 12 received 6.8 mg intranasal NPY, 18 placebo; MADRS assessed at baseline, +1h, +5h, +24h, +48h.
Why This Research Matters
One-third of depression patients don't respond to existing medications. NPY represents a completely novel mechanism — replacing a brain peptide that's depleted in depression.
The Bigger Picture
Like ketamine showed rapid antidepressant effects via a novel mechanism, intranasal NPY could represent another fast-acting approach. The neuropeptide replacement concept is compelling for neuropsychiatric disorders.
What This Study Doesn't Tell Us
Very small sample (n=30, unequal groups 12 vs 18); primary endpoint at 48h not met; single dose — duration of effect unknown with repeated dosing; add-on to antidepressants only.
Questions This Raises
- ?Would repeated daily intranasal NPY produce sustained antidepressant effects?
- ?What dose provides the best balance of efficacy and duration?
- ?Could NPY work as monotherapy, or only as add-on?
Trust & Context
- Key Stat:
- MADRS -10.3 at 24h Single intranasal NPY dose reduced depression scores twice as much as placebo at 24 hours
- Evidence Grade:
- Moderate — first-in-kind RCT with significant secondary endpoint but missed primary endpoint; small sample size.
- Study Age:
- Published in 2020; intranasal peptide delivery for neuropsychiatric disorders is an emerging field.
- Original Title:
- A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.
- Published In:
- The international journal of neuropsychopharmacology, 23(12), 783-790 (2020)
- Authors:
- Mathé, Aleksander A(4), Michaneck, Miranda, Berg, Elisabeth, Charney, Dennis S, Murrough, James W
- Database ID:
- RPEP-04988
Evidence Hierarchy
Frequently Asked Questions
What is neuropeptide Y?
A naturally occurring brain chemical that promotes resilience and stress resistance. People with depression and PTSD have lower levels of NPY in their brain fluid.
How does a nasal spray reach the brain?
The nose has direct neural pathways to the brain. Intranasal delivery allows peptides to bypass the blood-brain barrier and reach brain regions involved in mood regulation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04988APA
Mathé, Aleksander A; Michaneck, Miranda; Berg, Elisabeth; Charney, Dennis S; Murrough, James W. (2020). A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.. The international journal of neuropsychopharmacology, 23(12), 783-790. https://doi.org/10.1093/ijnp/pyaa054
MLA
Mathé, Aleksander A, et al. "A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.." The international journal of neuropsychopharmacology, 2020. https://doi.org/10.1093/ijnp/pyaa054
RethinkPeptides
RethinkPeptides Research Database. "A Randomized Controlled Trial of Intranasal Neuropeptide Y i..." RPEP-04988. Retrieved from https://rethinkpeptides.com/research/mathe-2020-a-randomized-controlled-trial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.